FDA
-
-
-
-
-
-
-
Dr. Reddy’s Q4 & Full Year FY25 Financial Results
-
-
-
-
-
-
-
Dr. Reddy’s Q3 & 9M FY24 Financial Results
-
-
-
-
-
-
-
Dr. Reddys Labs (RDY) Announces Launch of Fesoterodine Fumarate Extended-Release Tablets in the U.S. Market
-
-
-
-
-
-
-
Dr. Reddy's Laboratories Announces the Launch of Its Authorized Generic Version of VASOSTRICT® (vasopressin injection, USP) Vials in the U.S. Market
-
-
-
-
-
-
-
Dr. Reddy's Laboratories Announces the Launch of Carmustine for Injection, USP in the U.S. Market
-
-
-
-
-
-
-
Dr. Reddy's Laboratories Announces the Launch of a Generic Version of Sapropterin Dihydrochloride Powder for Oral Solution, 100 mg in the U.S. Market
-
-
-
-
-
-
-
Dr. Reddy’s announces the re-launch of over-the-counter Famotidine Tablets USP, 10 mg and 20 mg, store-brand equivalent of Pepcid AC® in the U.S. Market
-
322,969 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

